MoonLake Clears Key Regulatory Hurdle, Shares Surge

What happened

Shares of MoonLake Immunotherapeutics surged after the company announced a favorable FDA meeting in April regarding the regulatory path for its HS program. The FDA accepted the company's proposal to use pooled and treatment-policy analyses from the mixed Phase 3 VELA trials to support a BLA filing, reducing the risk of needing an additional pivotal trial. This development partially de-risks the near-term regulatory overhang that had weighed on the stock since the mixed results in September 2025. However, the long-term thesis still depends on 52-week durability data from the HS program and upcoming Phase 3 readouts in PsA and other indications. The company's cash position remains tight, but the regulatory clarity improves its ability to secure non-dilutive financing.

Implication

The FDA's acceptance of pooled analyses for the HS program is a significant positive that removes a key binary risk and supports a more constructive view. However, the story is not yet derisked: we still need 52-week HS data and Phase 3 PsA results in 2026. Investors should look for demonstrated durability and safety in those readouts before becoming more aggressive. The improved regulatory outlook also enhances the company's financing prospects, potentially reducing dilution risk. Given the remaining uncertainties and the stock's run-up, we recommend holding but upgrading to buy only on further confirmatory data.

Thesis delta

We shift from a HOLD/NEUTRAL stance to a more constructive but still cautious HOLD, as the FDA acceptance of pooled analyses reduces the probability of a worst-case outcome requiring a new pivotal HS trial. The key risk of regulatory rejection has been substantially mitigated, but the thesis still depends on positive 52-week HS data and successful PsA Phase 3 results. The near-term risk/reward has improved, but we need to see execution on the remaining catalysts before upgrading to BUY.